OPKO Health Taps Royalty Streams for $125M Senior Secured Notes
OPK sits 41% above its 52-week low of $0.977.
Summary
OPKO Health issued $125 million in additional senior secured notes, secured by royalty streams from mazdutide and Pfizer profit-share payments, with interest at SOFR + 7.5% and maturity in 2044.
Key Events · Financing and Capital Events · OPK
-
Additional Notes Issued
Under an amended Note Purchase Agreement dated August 13, 2026, the company issued $125 million in additional senior secured notes.
-
Interest Rate and Maturity
The notes bear interest at 3-month SOFR (floor 4.0%) plus 7.5% per annum, maturing July 17, 2044.
-
Collateral and Payment Structure
They are secured by EirGen's royalty interest in mazdutide and Pfizer profit-share payments; Mazdutide Payments are capped at $187.5 million.
-
Use of Proceeds
Proceeds are not specified in the filing; the financing adds to existing debt obligations.
Analysis · OPK · Life Sciences
The company raised $125 million through additional senior secured notes, leveraging its royalty interests in mazdutide and Pfizer profit-share payments. The notes carry a high interest rate of SOFR + 7.5% (with a 4% floor), reflecting the company's credit profile. This financing provides liquidity but adds significant debt service obligations, with interest payments tied to royalty cash flows. The cap on Mazdutide Payments at $187.5 million limits the collateral available to noteholders.
How filings like this one have moved
In the 30 days to Oct 1, 2026, 30.2% of the 1625 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.52%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, OPK was trading at $1.38 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1B. The 52-week trading range was $0.98 to $1.73. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.